The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase I study of  EpCAM/CD3-bispecific antibody (MT110) in patients with advanced solid tumors.
Walter M. Fiedler
No relevant relationships to disclose
Martin Wolf
No relevant relationships to disclose
Maxim Kebenko
No relevant relationships to disclose
Marie-Elisabeth Goebeler
No relevant relationships to disclose
Barbara Ritter
No relevant relationships to disclose
Alexander Quaas
No relevant relationships to disclose
Eva Vieser
Employment or Leadership Position - Micromet
Youssef Hijazi
Employment or Leadership Position - Micromet
Ingrid Patzak
Employment or Leadership Position - Micromet
Matthias Friedrich
Employment or Leadership Position - Micromet
Peter Kufer
Employment or Leadership Position - Micromet
Stock Ownership - Micromet
Other Remuneration - Micromet
Stanley Frankel
Employment or Leadership Position - Micromet
Stock Ownership - Micromet
Ruth Seggewiss-Bernhardt
No relevant relationships to disclose
Sabine Kaubitzsch
Employment or Leadership Position - Micromet